Sorriso Pharmaceuticals, Inc.

Sorriso Pharmaceuticals, Inc. specializes in developing innovative oral antibody therapies to target immune-mediated diseases, enhancing treatment options for patients suffering from chronic inflammatory conditions. Founded in 2020 and headquartered in San Diego, US, Sorriso Pharmaceuticals focuses on advancing oral antibody therapies. The company raised USD 31 mn in Series A funding on December 22, 2021, co-led by New Enterprise Associates and Arix Bioscience.

Ciara Kennedy serves as the CEO. Sorriso Pharmaceuticals focuses on developing innovative oral antibody therapies targeting immune-mediated diseases. Their core products include the SOR101, SOR102, and SOR104 programs aimed at addressing unmet medical needs, such as ulcerative colitis, utilizing novel oral antibodies to enhance treatment outcomes compared to traditional therapies. Sorriso Pharmaceuticals generates revenue through clinical development programs and strategic partnerships with healthcare organizations.

Their revenue model includes milestone payments and royalties based on the commercialization of products, such as SOR102, ensuring engagement with clients and stakeholders throughout the development process. The recent Series A funding of USD 31 mn will be utilized to advance Sorriso Pharmaceuticals’ pipeline of novel oral antibodies aimed at addressing unmet needs in immune-mediated diseases. The company is also exploring expansion into additional international markets, although specific target regions and timelines have yet to be detailed.